Oncology - ePrescribing Toolkit

A total 1217 patients were randomised to the study. Gefitinib was administered in a dose of 250 mg orally, once daily, and carboplatin in a target dose using the area under the concentration versus time curve (AUC) of 5 or 6 (mg/mL.min) intravenous (IV) on day one every three weeks plus paclitaxel 200 mg/m2 IV on day one every three weeks. ................
................